Citius Oncology (CTOR) Goodwill & Intangibles (2024 - 2026)
Citius Oncology (CTOR) posted quarterly Goodwill & Intangibles of $73.4 million for Q1 2026, up 0.79% quarter-over-quarter from $72.8 million in Q4 2025.
Citius Oncology (CTOR) Goodwill & Intangibles (2024 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Goodwill & Intangibles for 3 consecutive years, with $73.4 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.40 Mn |
| Dec 31, 2025 | 72.83 Mn |
| Dec 31, 2024 | 72.83 Mn |